➡️ The evolving paradigm of therapy in T-cell ALL by @NitinJainMD at US AML/ALL focus meet @_MDEducation ✅ Bcl2/BclXL inhibitors ✅ CD 7 CAR-Ts ✅ LCK inhibition by Dasatinib/Ponatinib https://t.co/btUp5uOKaW (@jayastuMD)

Great talk by @NitinJainMD on T-ALL ➡️ CAR-T cells being optimized with promising results ➡️ Rationale for inhibition of BCL-2 BCL-xl ➡️ LCK in 40% of T-ALL sensitive to dasatinib/ponatinib. Clinical trial at @MDAndersonNews with chemo-VEN-ponatinib #leusm #ALL @_MDEducation (@FadiHaddad_MD)

Dasatinib 50 mg daily is as effective and less toxic than 100 mg daily for newly diagnosed CML-CP Georgina Gener-Ricos @FadiHaddad_MD @MDAndersonNews @OncologyAdvance https://t.co/FbCwkDpo11 #leusm #CML (@DrHKantarjian)

With @YujiMiura5 in the renal cancer session in 🇯🇵 . Dr Ryosuke Oki described 4 treatment options for favourable risk clear cell patients, which appear mainly angiogenic driven. 4 options now 1) surveillance 2) VEGF/PD1 combos 3)sunitinib 4) surgery/RFA . #JSMO2023 (@tompowles1)

From @Nature, another potential targeted therapy for #melanoma, combining #sunitinib (already approved for other cancers) and a novel "BET" inhibitor that may work through suppressing GDF15 expression. I know, alphabet soup. https://t.co/KhpK5bps0M (@Melanoma_doctor)

Probably this is transformed AML from Eosinophilia. Just need to check if the NGS shows PDGFRA D842V mutation. If this mutation present , then it won’t respond to imatinib. Avapritinib is drug of choice. We had similar patient whom we transplanted in CR1. Relapsed with EM disez. (@SujayRainchwar)

Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study https://t.co/GGEBB7rbM6 (@drdeniztural)

Hot Topics in GU in Canary Islands. The clear benefits for VEGF/PD1 combs vs sunitinib in good risk mRCC is less clear looking maturing OS data. Also, ipi/nivo, which was initially worse than VEGF TKI now looks the same. @cdanicas @drenriquegrande @brian_rini @g_develasco (@tompowles1)

Hot Topics in GU in Canary Islands. The clear benefits for VEGF/PD1 combs vs sunitinib in good risk mRCC is less clear looking maturing OS data. Also, ipi/nivo, which was initially worse than VEGF TKI now looks the same. @cdanicas @Uromigos @brian_rini @g_develasco (@tompowles1)

Lenvatinib and pembro in non-clear cell (n=82) (mainly papillary RCC) looks impressive with RR =53% ( for papillary) . Maybe the combinations are better than historical controls for single agent VEGF TKIs. Randomised trials are hard to do, ipi/nivo vs sunitinib awaited #ESMO22 (@tompowles1)

Pegylated il-2 +nivo not beating sunitinib in 1st line advanced RCC. CR=2%, RR=23% (modest).Primary progression rates 15% higher than sunitinib! PFSnot shown (unusual) il-2 chapter closes. The PDL1 biomarker data +ve. Drug development stalled - It’s time for biomarkers #ESMO22 (@tompowles1)

New EAU and ESMO guidelines now aligned in 1st line RCC. Ipi/nivo for int/poor risk, VEGF/PD1 for all. No clear OS benefit in good risk RCC for VEGF/PD1 (vs sunitinib), but RR,PFS ⬆️therefore supported. PD1/VEGF combos data looks very similar-pick one use it well @Uroweb @myESMO (@tompowles1)

CM214 biomarker data (ipi/nivo vs sunitinib-RCC) 1)PD-L1 TC works for sunitinib >ipi/nivo 2)DNA mutations not helpful 3)inconsistent RNA results compared to previous data 4)Angio signatures work for both. Different immune combos have different biomarkers https://t.co/UkLD6ziRZg (@tompowles1)

KEYNOTE-811 → HER-2 gastric cancer → pembro+trastuzumab+chemo KEYNOTE 590 → Esophageal SCC → Pembro+Chemo JUPITER-06 → Esophageal SCC → toripalimab+ Chemo VOYAGER → PDGFRA D842V GIST → avapritinib vs. regorafenib (@AliAlqahtaniMD)

#ESMO21 : Very interesting findings of the FIRSTMAPP study showing promising activity of sunitinib in malignancy pheochromocytoma, particularly in patients with SDHB mutations!! @myESMO @OncoAlert (@DrChoueiri)

Open @MDAndersonNews #ClinicalTrial #2021-0331 Study of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Vs Placebo in Pts W/ Indolent Systemic Mastocytosis | PI: Prithviraj Bose @bose_prithviraj | NCT03731260 | https://t.co/JiwPVibHwR #leusm (@Lisa_Palacios)

At the EAU renal cancer guidelines meeting, discussing brain mets (imaging and RT), adjuvant pembrolizumab (y/n), relevant biomarkers (PDL1/RNA sigs), VHL, IMDC good risk (sunitinib: y/n) and non-clear cell RCC (which TKI vs IO) . Engaging debate with multidisciplinary friends. (@tompowles1)

Avapritinib now FDA-approved for adult pts with advanced systemic mastocytosis and its variants, incl. mast cell leukemia. Dose is lower (200 mg/day) than in PDGFRa-driven GIST. Early responses, good response rate and long-lasting disease control. Congratulations to Blueprint! (@schoffski)

.@JTrentMDPhD, MD, PhD, @SylvesterCancer discusses the role of avapritinib in PDGFRA exon 18–positive gastrointestinal stromal tumor. #scmsm https://t.co/IL6jMnwHsI (@OncLive)

This @practiceupdate article written by @jgong15 highlights that sunitinib tx promotes metastasis of drug-resistant #RCC via #TFE3 signaling pathway. https://t.co/INDs2Xyepg (@montypal)

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial https://t.co/Np57Bz7aTv via @rightrelevance thanks @viveksubbiah (@ChocolatiereP)

NGS identified a case of a RET amplification as a potential basis of sensitivity to sunitinib in a patient with refractory germ cell tumor. https://t.co/SooG7mXFzU (@VivekSubbiah)

This week @benweinbergmd highlighted “Avapritinib in unresectable or metastatic PDGFRA D842V- mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial" @OncologyAdvance. View the full weekly list via: https://t.co/74fkdT4fhG (@RueschCenter)

Next week, I’ll evaluate a patient with metastatic GIST and PDGFRA D842V mutation. Avapritinib and ripretinib are not approved in Brazil. Is there a way for compassionate access to these drugs outside the USA? @JTrentMDPhD @DrCeSarcoma @Deciphera @BlueprintMeds @VivekSubbiah (@PestanaRC)

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial - ScienceDirect https://t.co/IqLLZXsm1l (@VivekSubbiah)

Avapritinib in advanced PDGFRA D842V-mutant #GIST ⁦@sciencedirect⁩ ⁦@TheLancetOncol⁩ ⁦@schoffski⁩ ⁦@RobinL_Jones⁩ ⁦@rutkowskip1972⁩ ⁦@WTapMD⁩ ⁦@DrCeSarcoma⁩ https://t.co/ZLS73J5rsX (@JTrentMDPhD)

Phase 1 study bevacizumab+dasatinib with interesting activity in #endometrial cancer @ASCO @NCIResearchCtr #ASCO17 (@CMAnnunziata)